Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Sunshine Biopharma, Inc. (SBFM)

2.7100 -0.0800 (-2.87%)
At close: November 6 at 4:00:00 PM EST
2.7000 -0.0100 (-0.37%)
After hours: November 6 at 4:04:29 PM EST
Chart Range Bar
Loading chart for SBFM
  • Previous Close 2.7900
  • Open 2.7300
  • Bid 3.0300 x 400
  • Ask 0.1448 x 100
  • Day's Range 2.6801 - 2.8500
  • 52 Week Range 2.5300 - 464.0000
  • Volume 36,590
  • Avg. Volume 298,312
  • Market Cap (intraday) 2.062M
  • Beta (5Y Monthly) 1.52
  • PE Ratio (TTM) --
  • EPS (TTM) -189.0000
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 1,120.00
  • Moby Rating Neutral

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications. Sunshine The company is based in Fort Lauderdale, Florida.

sunshinebiopharma.com

50

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SBFM
98.90%
S&P 500 (^GSPC)
7.76%

1-Year Return

SBFM
99.24%
S&P 500 (^GSPC)
9.77%

3-Year Return

SBFM
100.00%
S&P 500 (^GSPC)
68.96%

5-Year Return

SBFM
100.00%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 9.26M
Earnings -1.56M
Profit Margin -16.88%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-2M
0
2M
4M
6M
8M
-20.0%
-15.0%
-10.0%

Analyst Insights

View More

Analyst Price Targets

1,120.00
1,120.00 Average
2.7100 Current
1,120.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/8/2025
Analyst Aegis Capital
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 7 -> 7

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -16.50%

  • Return on Assets (ttm)

    -9.91%

  • Return on Equity (ttm)

    -21.92%

  • Revenue (ttm)

    35.35M

  • Net Income Avi to Common (ttm)

    -5.83M

  • Diluted EPS (ttm)

    -189.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    14.03M

  • Total Debt/Equity (mrq)

    2.46%

  • Levered Free Cash Flow (ttm)

    -2.01M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: